keyword
MENU ▼
Read by QxMD icon Read
search

Dyslipidemia, statins,

keyword
https://www.readbyqxmd.com/read/29774988/differences-in-primary-cardiovascular-disease-prevention-between-the-2013-and-2016-cholesterol-guidelines-and-impact-of-the-2017-hypertension-guideline-in-the-united-states
#1
Brent M Egan, Jiexiang Li, Robert A Davis, Kevin A Fiscella, Jonathan N Tobin, Daniel W Jones, Angelo Sinopoli
The US Preventive Services Task Force cholesterol guideline recommended statins for fewer adults than the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline by setting a higher 10-year atherosclerotic cardiovascular disease threshold (≥10.0% vs ≥7.5%) and requiring concomitant diabetes mellitus, hypertension, dyslipidemia, or cigarette smoking. The 2017 ACC/AHA hypertension guideline lowered the hypertension threshold, increasing 2016 guideline statin-eligible adults. Cross-sectional data on US adults aged 40 to 75 years enabled estimated numbers for the 2013 guideline and 2016 guideline with hypertension thresholds of ≥140/≥90 mm Hg and ≥130/80 mm Hg, respectively, on: (1) untreated, statin-eligible adults for primary atherosclerotic cardiovascular disease prevention (25...
May 18, 2018: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/29766349/recent-developments-in-the-role-of-coenzyme-q10-for-coronary-heart-disease-a-systematic-review
#2
REVIEW
Jessica Ayers, Jamie Cook, Rachel A Koenig, Evan M Sisson, Dave L Dixon
PURPOSE OF REVIEW: This review examines recent randomized clinical trials evaluating the role of coenzyme Q10 (CoQ10) in the management of coronary heart disease. RECENT FINDINGS: CoQ10 is one of the most commonly used dietary supplements in the USA. Due to its antioxidant and anti-inflammatory effects, CoQ10 has been studied extensively for possible use in managing coronary heart disease. One of the most common applications of CoQ10 is to mitigate statin-associated muscle symptoms (SAMS) based on the theory that SAMS are caused by statin depletion of CoQ10 in the muscle...
May 16, 2018: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/29765452/effects-and-potential-mechanism-of-atorvastatin-treatment-on-lp-pla2-in-rats-with-dyslipidemia
#3
Dongdan Zheng, Anping Cai, Rulin Xu, Zhuocheng Mai, Yingling Zhou, Fanfang Zeng, Liwen Li, Weiyi Mai
Introduction: The effects of statins on lipoprotein-associated phospholipase A2 (Lp-PLA2) are controversial, and the present study aimed to investigate whether atorvastatin could reduce Lp-PLA2 in rats with dyslipidemia. Material and methods: A high-fat and high-cholesterol diet was prescribed to produce a dyslipidemia model. Thereafter, low-dose atorvastatin (5 mg/kg/day), high-dose atorvastatin (20 mg/kg/day) or saline (without-treatment group) was prescribed for 14 days...
April 2018: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/29754909/serum-pcsk9-levels-predict-the-occurrence-of-acute-coronary-syndromes-in-patients-with-severe-carotid-artery-stenosis
#4
Luca Liberale, Federico Carbone, Maria Bertolotto, Aldo Bonaventura, Alessandra Vecchié, François Mach, Fabienne Burger, Aldo Pende, Giovanni Spinella, Bianca Pane, Giovanni G Camici, Domenico Palombo, Franco Dallegri, Fabrizio Montecucco
BACKGROUND: The pharmacological inhibition of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) has shown to dramatically impact on low-density lipoprotein-cholesterol (LDL-C) levels and associated cardiovascular (CV) diseases. However, the potential use of PCSK9 serum levels as a CV risk biomarker remains to be clarified. METHODS: 189 patients with severe carotid artery atherosclerosis undergoing carotid endarterectomy (CEA) and whose clinical records and serum sample aliquots for PCSK9 level measurement were available both directly before CEA and at 24-month follow-up were included in the present pilot study...
July 15, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29754716/sex-disparity-persists-in-the-prevention-of-cardiovascular-disease-in-women-on-statin-therapy-compared-to-that-in-men
#5
S Moreno-Arellano, J Delgado-de-Mendoza, M J Santi-Cano
BACKGROUND AND AIMS: The aim of this study was to assess whether women differ from men with regard to lowering lipid levels, achieving target of optimal lipid levels, and analyzing evidence-based dose and intensity of statin prescription in primary care patients. METHODS AND RESULTS: A multicenter cross-sectional survey was conducted among 1046 patients with dyslipidemia (554 women) who were receiving statin therapy from the Primary Health Care of Andalucía (Spain)...
April 7, 2018: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/29753732/niacin-action-in-the-atherogenic-mixed-dyslipidemia-of-metabolic-syndrome-insights-from-metabolic-biomarker-profiling-and-network-analysis
#6
Martin Adiels, M John Chapman, Paul Robillard, Michel Krempf, Martine Laville, Jan Borén
BACKGROUND: Niacin as an adjunct to statin treatment to reduce cardiovascular risk is questioned. OBJECTIVE: To evaluate interrelationships between the effects of niacin on mixed dyslipidemia and a spectrum of metabolic and inflammatory biomarkers. METHODS: Obese, nondiabetic, hypertriglyceridemic males (n = 19) with low high-density lipoprotein-cholesterol levels received extended-release nicotinic acid for 8 weeks. Multiple biomarkers were measured using enzyme-linked immunosorbent assay, enzymatic/absorptiometric, or multiplex biochip assays...
March 29, 2018: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29732606/influence-of-6-genetic-variants-on-the-efficacy-of-statins-in-patients-with-dyslipidemia
#7
Ruth Cano-Corres, Beatriz Candás-Estébanez, Ariadna Padró-Miquel, Marta Fanlo-Maresma, Xavier Pintó, Pedro Alía-Ramos
BACKGROUND: Patients with dyslipidemia are often treated with statins to reduce lipids and hence cardiovascular risk, but treatment response is variable, partly due to genetic factors. METHODS: We studied the influence of 6 gene variants (APOE c.526C > T (APOE2), APOE c.388T > C (APOE4), SLCO1B1 c.521T > C, CYP3A4 c.-392G > A, HMGCR c.1564-106A > G, and LPA c.3947 + 467T > C) on statin efficacy assessing 2 indicators: the percent reduction in total cholesterol (TC) and non-HDL cholesterol (non-HDL), as well as the achievement of therapeutic goals...
May 7, 2018: Journal of Clinical Laboratory Analysis
https://www.readbyqxmd.com/read/29709973/short-term-efficacy-and-safety-of-adding-ezetimibe-to-currently-used-lipid-lowering-drugs-in-thai-hiv-infected-patients-receiving-protease-inhibitors
#8
Krisda Boonthos, Chankit Puttilerpong, Thitima Pengsuparp, Weerawat Manosuthi
Long-term complication of protease inhibitors (PIs) includes increased cardiovascular risks in HIV-infected patients due to dyslipidemia. Ezetimibe reduces LDL-C without drug interaction to PIs and statins. Furthermore, addition of ezetimibe on statins is an optional treatment in HIV-infected patients with uncontrolled dyslipidemia. The objective of this study was to determine short-term efficacy and safety of adding ezetimibe to currently used statins. Thirty-two patients received ezetimibe 10 mg daily added to their ongoing lipid-lowering therapy for 18 weeks...
April 27, 2018: Japanese Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29708925/unexplained-reciprocal-regulation-of-diabetes-and-lipoproteins
#9
Sei Higuchi, M Concepción Izquierdo, Rebecca A Haeusler
PURPOSE OF REVIEW: Type 2 diabetes is associated with a characteristic dyslipidemia that may exacerbate cardiovascular risk. The causes of, and the effects of new antihyperglycemia medications on, this dyslipidemia, are under investigation. In an unexpected reciprocal manner, lowering LDL-cholesterol with statins slightly increases the risk of diabetes. Here we review the latest findings. RECENT FINDINGS: The inverse relationship between LDL-cholesterol and diabetes has now been confirmed by multiple lines of evidence...
June 2018: Current Opinion in Lipidology
https://www.readbyqxmd.com/read/29707830/esrd-induced-dyslipidemia-should-management-of-lipid-disorders-differ-in-dialysis-patients
#10
Hamid Moradi, Elani Streja, Nosratola D Vaziri
Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide. Although numerous modifiable risk factors in the pathogenesis of CVD and its associated mortality have been identified, dyslipidemia remains to be a key focus for therapy. In this regard, significant progress has been made in reducing cardiovascular mortality via the use of lipid-lowering agents such as HMG CoA reductase inhibitors (statins). Yet, despite the disproportionate risk of CVD and mortality in patients with advanced chronic and end stage renal disease (ESRD), treatment of dyslipidemia in this patient population has not been associated with a notable improvement in outcomes...
April 29, 2018: Seminars in Dialysis
https://www.readbyqxmd.com/read/29696241/blood-pressure-and-metabolic-effects-of-acetyl-l-carnitine-in-type-2-diabetes-diabasi-randomized-controlled-trial
#11
Aneliya Parvanova, Matias Trillini, Manuel A Podestà, Ilian P Iliev, Carolina Aparicio, Annalisa Perna, Francesco Peraro, Nadia Rubis, Flavio Gaspari, Antonio Cannata, Silvia Ferrari, Antonio C Bossi, Roberto Trevisan, Sreejith Parameswaran, Jonathan S Chávez-Iñiguez, Fahrudin Masnic, Sidy Mohamed Seck, Teerayuth Jiamjariyaporn, Monica Cortinovis, Luca Perico, Kanishka Sharma, Giuseppe Remuzzi, Piero Ruggenenti, David G Warnock
Context: Acetyl-l-carnitine (ALC), a mitochondrial carrier involved in lipid oxidation and glucose metabolism, decreased systolic blood pressure (SBP), and ameliorated insulin sensitivity in hypertensive nondiabetic subjects at high cardiovascular risk. Objective: To assess the effects of ALC on SBP and glycemic and lipid control in patients with hypertension, type 2 diabetes mellitus (T2D), and dyslipidemia on background statin therapy. Design: After 4-week run-in period and stratification according to previous statin therapy, patients were randomized to 6-month, double-blind treatment with ALC or placebo added-on simvastatin...
May 1, 2018: Journal of the Endocrine Society
https://www.readbyqxmd.com/read/29694290/the-effect-of-clinical-pharmacist-led-comprehensive-medication-management-on-chronic-disease-state-goal-attainment-in-a-patient-centered-medical-home
#12
Jarred Prudencio, Timothy Cutler, Stephanie Roberts, Stephanie Marin, Machelle Wilson
BACKGROUND: Clinical pharmacy services were initiated at 7 of 11 clinics within a primary care network (PCN), which was designated as a patient-centered medical home and was affiliated with a large academic medical center in October 2014. The goal of the service was to target patients with uncontrolled chronic conditions, specifically diabetes. Patients met with a clinical pharmacist through individual clinic and telephonic appointments, in addition to usual appointments with physicians as needed...
May 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29683005/association-between-adherence-to-statins-illness-perception-treatment-satisfaction-and-quality-of-life-among-lebanese-patients
#13
Christine Haddad, Souheil Hallit, Mohammad Salhab, Aline Hajj, Antoine Sarkis, Eliane Nasser Ayoub, Hicham Jabbour, Lydia Rabbaa Khabbaz
OBJECTIVES: The main objective of this study was to evaluate treatment adherence to statin and health-related quality of life (QOL) in Lebanese patients with dyslipidemia. Secondary objectives were to examine associations between treatment adherence, QOL, treatment satisfaction, and illness perception. METHODS: This cross-sectional study, conducted in 20 community pharmacies from all districts of Lebanon between August 2016 and April 2017, enrolled 247 adult patients taking any statin...
January 1, 2018: Journal of Cardiovascular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29672173/the-potential-role-of-statins-in-preeclampsia-and-dyslipidemia-during-gestation-a-narrative-review
#14
Serban M Maierean, Dimitri P Mikhailidis, Peter P Toth, Mariusz Grzesiak, Moshen Mazidi, Marek Maciejewski, Maciej Banach
Statins have several pleiotropic effects that have the potential to be beneficial during pregnancy. This study evaluates the available evidence for the teratogenicity of statins, and their utility in treating preeclampsia and dyslipidemia in pregnancy, as good alternatives in these domains are currently lacking. Areas covered: The possible teratogenicity of statins is a primary focus of this paper. We also evaluated for some possible non-teratogenic effects, such as changes in birth weight and rates of spontaneous abortion, among mothers exposed to statins during pregnancy...
April 19, 2018: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/29666753/effect-of-metformin-monotherapy-on-serum-lipid-profile-in-statin-na%C3%A3-ve-individuals-with-newly-diagnosed-type-2-diabetes-mellitus-a-cohort-study
#15
Szu Han Lin, Po Chung Cheng, Shih Te Tu, Shang Ren Hsu, Yun Chung Cheng, Yu Hsiu Liu
Background: Cardiovascular disease is a major cause of mortality and morbidity in people with type 2 diabetes mellitus (T2DM). Studies have consistently identified dyslipidemia as an important risk factor for the development of macrovascular disease. The landmark United Kingdom Prospective Diabetes Study has shown that metformin therapy reduces cardiovascular events in overweight people with T2DM. This study investigates the effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed T2DM, and whether the effect, if any, is dosage-related...
2018: PeerJ
https://www.readbyqxmd.com/read/29651791/a-discrete-event-simulation-model-to-assess-the-economic-value-of-a-hypothetical-pharmacogenomics-test-for-statin-induced-myopathy-in-patients-initiating-a-statin-in-secondary-cardiovascular-prevention
#16
Dominic Mitchell, Jason R Guertin, Anick Dubois, Marie-Pierre Dubé, Jean-Claude Tardif, Ange Christelle Iliza, Fiorella Fanton-Aita, Alexis Matteau, Jacques LeLorier
BACKGROUND: Statin (HMG-CoA reductase inhibitor) therapy is the mainstay dyslipidemia treatment and reduces the risk of a cardiovascular (CV) event (CVE) by up to 35%. However, adherence to statin therapy is poor. One reason patients discontinue statin therapy is musculoskeletal pain and the associated risk of rhabdomyolysis. Research is ongoing to develop a pharmacogenomics (PGx) test for statin-induced myopathy as an alternative to the current diagnosis method, which relies on creatine kinase levels...
April 12, 2018: Molecular Diagnosis & Therapy
https://www.readbyqxmd.com/read/29628458/low-density-lipoprotein-cholesterol-goal-attainment-rates-by-initial-statin-monotherapy-among-patients-with-dyslipidemia-and-high-cardiovascular-risk-in-japan-a-retrospective-database-analysis
#17
Tatsuya Umeda, Ai Hayashi, Akiko Harada, Kotoba Okuyama, Carl A Baxter, Shigeru Tokita, Tamio Teramoto
BACKGROUND: To understand the recent management status in Japan, we determined the low-density lipoprotein cholesterol (LDL-C) goal attainment (GA) rate of patients initiating statin monotherapy for dyslipidemia.Methods and Results:Dyslipidemic patients undergoing either primary prevention with high cardiovascular risk or secondary prevention (defined by 2012 Japan Atherosclerosis Society Guidelines) were retrospectively analyzed from a hospital-based claims database. In both groups, the LDL-C levels and GA rates of patients treated with intensive or standard statin monotherapy for ≥4 weeks (January 2012-August 2016) were evaluated...
April 7, 2018: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/29626074/intensive-treat-to-target-statin-therapy-in-high-risk-japanese-patients-with-hypercholesterolemia-and-diabetic-retinopathy-report-of-a-randomized-study
#18
Hiroshi Itoh, Issei Komuro, Masahiro Takeuchi, Takashi Akasaka, Hiroyuki Daida, Yoshiki Egashira, Hideo Fujita, Jitsuo Higaki, Ken-Ichi Hirata, Shun Ishibashi, Takaaki Isshiki, Sadayoshi Ito, Atsunori Kashiwagi, Satoshi Kato, Kazuo Kitagawa, Masafumi Kitakaze, Takanari Kitazono, Masahiko Kurabayashi, Katsumi Miyauchi, Tomoaki Murakami, Toyoaki Murohara, Koichi Node, Susumu Ogawa, Yoshihiko Saito, Yoshihiko Seino, Takashi Shigeeda, Shunya Shindo, Masahiro Sugawara, Seigo Sugiyama, Yasuo Terauchi, Hiroyuki Tsutsui, Kenji Ueshima, Kazunori Utsunomiya, Masakazu Yamagishi, Tsutomu Yamazaki, Shoei Yo, Koutaro Yokote, Kiyoshi Yoshida, Michihiro Yoshimura, Nagahisa Yoshimura, Kazuwa Nakao, Ryozo Nagai
OBJECTIVE: Diabetes is associated with high risk of cardiovascular (CV) events, particularly in patients with dyslipidemia and diabetic complications. We investigated the incidence of CV events with intensive or standard lipid-lowering therapy in patients with hypercholesterolemia, diabetic retinopathy, and no history of coronary artery disease (treat-to-target approach). RESEARCH DESIGN AND METHODS: In this multicenter, prospective, randomized, open-label, blinded end point study, eligible patients were randomly assigned (1:1) to intensive statin therapy targeting LDL cholesterol (LDL-C) <70 mg/dL ( n = 2,518) or standard statin therapy targeting LDL-C 100-120 mg/dL ( n = 2,524)...
April 6, 2018: Diabetes Care
https://www.readbyqxmd.com/read/29624871/utilization-of-aspirin-and-statin-in-management-of-coronary-artery-disease-in-patients-with-cirrhosis-undergoing-liver-transplant-evaluation
#19
Samarth S Patel, Luis Guzman, Fei-Pi Lin, Taylor Pence, Trevor Reichman, Binu John, Francesco S Celi, Erika Liptrap, Chandra Bhati, Mohammad S Siddiqui
Coronary artery disease (CAD) assessment is vital part of liver transplantation (LT) evaluation as it allows for identification and medical optimization prior to transplantation. Although aspirin and statins are standard of care for CAD, they are not universally used in cirrhosis due to concerns of adverse events. METHODS: Per protocol, coronary angiography was performed as part of LT evaluation in all patients over the age of 50 years or with CAD risk factors even if they were younger than 50...
April 6, 2018: Liver Transplantation
https://www.readbyqxmd.com/read/29609929/red-yeast-rice-ryr-supplementation-in-patients-treated-with-second-generation-antipsychotics
#20
Antonio Bruno, Gianluca Pandolfo, Manuela Crucitti, Giulia Maria Troili, Edoardo Spina, Rocco Antonio Zoccali, Maria Rosaria Anna Muscatello
OBJECTIVE: Second-generation antipsychotics (SGAs) have a negative impact on metabolic syndrome (MetS) risk factors for their effects on body weight and on metabolic parameters. Statins are widely used in the treatment of dyslipidemia; less is known on the ability of statins to treat SGAs-induced dyslipidemia, and nutraceutical approaches may represent promising strategies in SGAs-treated patients. Red Yeast Rice (RYR), the fermented product of the Aspergillaceae mold Monascus purpureus (red yeast) grown on white rice, has been shown to have a cholesterol-lowering effect which can be ascribed to monacolin K, although other active compounds may play a role management of hyperlipidemia...
April 2018: Complementary Therapies in Medicine
keyword
keyword
118412
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"